The hearing will focus on the therapeutic potential and ethical issues of using CRISPR technology to alter human DNA.
The CEO of Cambridge gene editing biotech Editas Medicine will testify next week during a U.S. Senate hearing focused on the therapeutic potential and ethical issues of using CRISPR technology to alter human DNA.
The U.S. Senate Committee on Health, Education, Labor and Pensions, or HELP, announced Tuesday that it would hold the hearing, titled “Gene Editing Technology: Innovation and Impact,” on Nov. 14. Editas (Nasdaq: EDIT) CEO Katrine Bosley is one of three experts scheduled to testify, along with Stanford University professor Matthew Porteus and Johns Hopkins University professor Jeffrey Kahn.
